GlaxoSmithKline PLC ADRGSK

GSK current price
$33.82-10.03%

Capital at risk.

1W
-0.56%
1M
-2.40%
3M
-11.88%
6M
-11.09%
1Y
-10.03%
MAX
+31.29%
Calendar
event
Ex dividend date
15 Nov 2024
calendar_clock
Next Dividend Payment
09 Jan 2025
About GlaxoSmithKline PLC ADR
Ticker
info
GSK
Trading on
info
NYSE
ISIN
info
US37733W2044
Industry
info
Drug Manufacturers - General
Sector
info
Healthcare
CEO
info
Emma Natasha Walmsley
Headquarters
info
980 Great West Road, Brentford, undefined, United Kingdom, TW8 9GS
Employees
info
70,212
Website
info
gsk.com
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Metrics
BasicAdvanced
Market cap
info
$68.7B
P/E ratio
info
21.99
EPS
info
$1.53
Dividend Yield
info
4.65%
Beta
info
0.33
Forward P/E ratio
info
7.73
EBIDTA
info
$9.26B
Ex dividend date
info
2024-11-15
Price & volume
Market cap
info
$68.7B
Average daily volume
info
4M
90-day return
info
-11.88%
30-day return
info
-2.40%
7-day return
info
-0.56%
Dividends
Dividend per share
info
$0.61
Dividend yield
info
4.65%
Forward dividend per share
info
$1.56
Forward dividend yield
info
4.65%
Payout ratio
info
37.07%
Valuation
P/E ratio
info
21.99
Forward P/E
info
7.73
PEG ratio
info
0.76
Trailing P/E
info
21.99
Price to sales
info
2.19
Price to book
info
3.9
Earnings
EPS
info
$1.53
EPS estimate (current quarter)
info
$1.23
EPS estimate (next quarter)
info
$0.58
EBITDA
info
$9.26B
Revenues (TTM)
info
$31.3B
Revenues per share (TTM)
info
$15.38
Technicals
Beta
info
0.33
52-week High
info
$44.85
52-week Low
info
$32.83
50-day moving average
info
$35.24
200-day moving average
info
$39.82
Short ratio
info
3.29
Short %
info
0.90%
Management effectiveness
ROE (TTM)
info
21.85%
ROA (TTM)
info
7.24%
Profit margin
info
8.02%
Gross profit margin
info
$19.9B
Operating margin
info
8.33%
Growth
Quarterly earnings growth (YoY)
info
28.20%
Quarterly revenue growth (YoY)
info
1.70%
Share stats
Outstanding Shares
info
2.04B
Float
info
3.95B
Insiders %
info
0.06%
Institutions %
info
15.39%
Analyst Insights & forecasts
info

44% Buy

42% Hold

14% Sell

Based on information from 7 analysts.

Average price target

info
$45.07
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.72
$0.76
5.26%
Q4 • 23Beat
$1.09
$0.91
19.78%
Q1 • 24Beat
$1.10
$0.99
11.11%
Q2 • 24Beat
$1.29
$1.23
4.88%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$7.88B
$1.17B
14.88%
Q2 • 24
$8.01B
$-58M
0.72%
Q3 • 24
1.62%
104.94%
104.87%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$58.1B
$44.3B
76.29%
Q2 • 24
$58B
$44.6B
76.82%
Q3 • 24
0.03%
0.68%
0.71%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$882M
$770M
$-1.31B
$440M
Q2 • 24
$2.15B
$-731M
$-1.24B
$1.31B
Q3 • 24
144.22%
194.94%
5.63%
198.18%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Extreme greed

+1.5

1.29

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a GlaxoSmithKline PLC ADR share?
Collapse

GlaxoSmithKline PLC ADR shares are currently traded for $33.82 per share.

How many shares does GlaxoSmithKline PLC ADR have?
Collapse

GlaxoSmithKline PLC ADR currently has 2.04B shares.

Does GlaxoSmithKline PLC ADR pay dividends?
Collapse

Yes, GlaxoSmithKline PLC ADR does pay dividends.

What is GlaxoSmithKline PLC ADR 52 week high?
Collapse

GlaxoSmithKline PLC ADR 52 week high is $44.85.

What is GlaxoSmithKline PLC ADR 52 week low?
Collapse

GlaxoSmithKline PLC ADR 52 week low is $32.83.

What is the 200-day moving average of GlaxoSmithKline PLC ADR?
Collapse

GlaxoSmithKline PLC ADR 200-day moving average is $39.82.

Who is GlaxoSmithKline PLC ADR CEO?
Collapse

The CEO of GlaxoSmithKline PLC ADR is Emma Natasha Walmsley.

How many employees GlaxoSmithKline PLC ADR has?
Collapse

GlaxoSmithKline PLC ADR has 70,212 employees.

What is the market cap of GlaxoSmithKline PLC ADR?
Collapse

The market cap of GlaxoSmithKline PLC ADR is $68.7B.

What is the P/E of GlaxoSmithKline PLC ADR?
Collapse

The current P/E of GlaxoSmithKline PLC ADR is 21.99.

What is the EPS of GlaxoSmithKline PLC ADR?
Collapse

The EPS of GlaxoSmithKline PLC ADR is $1.53.

What is the PEG Ratio of GlaxoSmithKline PLC ADR?
Collapse

The PEG Ration of GlaxoSmithKline PLC ADR is 0.76.

What do analysts say about GlaxoSmithKline PLC ADR?
Collapse

According to the analysts GlaxoSmithKline PLC ADR is considered a buy.